» Articles » PMID: 31760377

Exploring the Potential of MicroRNA Let-7c As a Therapeutic for Prostate Cancer

Overview
Publisher Cell Press
Date 2019 Nov 25
PMID 31760377
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) is one of the leading causes of mortality worldwide and often presents with aberrant microRNA (miRNA) expression. Identifying and understanding the unique expression profiles could aid in the detection and treatment of this disease. This review aims to identify miRNAs as potential therapeutic targets for PCa. Three bio-informatic searches were conducted to identify miRNAs that are reportedly implicated in the pathogenesis of PCa. Only hsa-Lethal-7 (let-7c), recognized for its role in PCa pathogenesis, was common to all three databases. Three further database searches were conducted to identify known targets of hsa-let-7c. Four targets were identified, HMGA2, c-Myc (MYC), TRAIL, and CASP3. An extensive review of the literature was undertaken to assess the role of hsa-let-7c in the progression of other malignancies and to evaluate its potential as a therapeutic target for PCa. The heterogeneous nature of cancer makes it logical to develop mechanisms by which the treatment of malignancies is tailored to an individual, harnessing specific knowledge of the underlying biology of the disease. Resetting cellular miRNA levels is an exciting prospect that will allow this ambition to be realized.

Citing Articles

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.


Decoding high mobility group A2 protein expression regulation and implications in human cancers.

Khazem F, Zetoune A Discov Oncol. 2024; 15(1):322.

PMID: 39085703 PMC: 11291832. DOI: 10.1007/s12672-024-01202-x.


A study of microRNAs as new prognostic biomarkers in anal cancer patients.

Dahl O, Myklebust M Acta Oncol. 2024; 63:456-465.

PMID: 38899393 PMC: 11332526. DOI: 10.2340/1651-226X.2024.27976.


Cross Talk between MicroRNAs and Dengue Virus.

Macha N, Komarasamy T, Harun S, Adnan N, Hassan S, Balasubramaniam V Am J Trop Med Hyg. 2024; 110(5):856-867.

PMID: 38579704 PMC: 11066346. DOI: 10.4269/ajtmh.23-0546.


PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway.

Liu T, Zhang J, Chen H, Bianba T, Pan Y, Wang X Oncogenesis. 2022; 11(1):12.

PMID: 35256584 PMC: 8901802. DOI: 10.1038/s41389-022-00386-7.


References
1.
Winter R, Kramer A, Borkowski A, Kyprianou N . Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001; 61(3):1227-32. View

2.
Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

3.
Du W, Hong L, Yao T, Yang X, He Q, Yang B . Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg Med Chem. 2007; 15(18):6323-30. DOI: 10.1016/j.bmc.2007.04.002. View

4.
Zhang W, Le T, Liu L, Zhou Z, Li J . Predicting miRNA Targets by Integrating Gene Regulatory Knowledge with Expression Profiles. PLoS One. 2016; 11(4):e0152860. PMC: 4827848. DOI: 10.1371/journal.pone.0152860. View

5.
Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View